PEDS-01: Normal Development and Developmental Assessment — Part 2 (Part 2 of 2)

Section 5: Developmental Surveillance, Screening, and the Diagnostic Toolkit

~3:30 – Developmental Surveillance, Screening, and the Diagnostic Toolkit

Bottom line: developmental surveillance is a continuous longitudinal process at every well-child visit, while standardized screening uses a validated instrument at the AAP anchor visits of 9, 18, and 30 months with autism-specific screening at 18 and 24 months; the Denver II, the Ages and Stages Questionnaire Third Edition (ASQ-3), the Parents’ Evaluation of Developmental Status (PEDS), and the Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F) are screening instruments designed to identify children who need further evaluation, while the Bayley Scales of Infant and Toddler Development Fourth Edition (Bayley-4) is the diagnostic gold standard with composite scores set at mean 100 and standard deviation 15; the developmental quotient equals developmental age divided by chronological age multiplied by 100 and uses corrected age in preterm infants; and the 2022 CDC and AAP milestone revision shifted from the 50th-percentile cutoff to the 75th-percentile cutoff with binary, observable criteria.

The American Academy of Pediatrics (AAP) framework draws a sharp line between two distinct activities. Developmental surveillance is the ongoing longitudinal process of eliciting parental concerns, observing the child, identifying risk and protective factors, and documenting developmental progress at every well-child visit from birth onward. It does not require a validated instrument. Developmental screening, by contrast, is the administration of a standardized validated instrument at predetermined anchor visits, with a defined cutoff that triggers further evaluation. The AAP schedule sets standardized developmental screening at 9, 18, and 30 months and autism-specific screening at 18 and 24 months. The 18-month visit is the only anchor where both general developmental and autism-specific screening occur simultaneously.

The Denver Developmental Screening Test, Second Edition (Denver II) is a clinician-administered screening tool spanning birth to 6 years across 4 domains: gross motor, fine motor-adaptive, language, and personal-social. It contains 125 items. Results are classified as normal, suspect, or untestable. A normal result requires no delays and at most 1 caution. A suspect result reflects 1 or more delays and/or 2 or more cautions. An untestable result reflects too many refusals to interpret. A caution is failure on an item passed by 75 to 90 percent of children at that age; a delay is failure on an item passed by more than 90 percent of children at that age, meaning the item line lies entirely to the left of the child’s chronological age. The Denver II does not generate a developmental quotient. Sensitivity ranges from 56 to 83 percent and specificity from 43 to 80 percent. It is a screening tool, not a diagnostic tool.

The Ages and Stages Questionnaire, Third Edition (ASQ-3) is a parent-completed screening tool covering 5 domains (communication, gross motor, fine motor, problem solving, and personal-social) across 21 age-specific forms spanning 1 to 66 months. Parent completion takes 10 to 15 minutes; clinician scoring takes 2 to 3 minutes. Sensitivity is 70 to 90 percent and specificity 76 to 91 percent. The ASQ-3 has largely supplanted the Denver II in many clinical settings because of better psychometric properties, lower clinician burden, and the inclusion of a “monitoring zone” between clear pass and clear referral that prompts close follow-up without immediate referral. The Parents’ Evaluation of Developmental Status (PEDS) is a 10-item parent interview tool for birth to 8 years that captures parental concerns rather than directly testing the child, with sensitivity 74 to 79 percent and specificity 70 to 80 percent.

The Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) is the diagnostic gold standard for ages 1 to 42 months. It is clinician-administered and covers 5 scales: Cognitive, Language, Motor, Social-Emotional, and Adaptive Behavior. Composite scores are scaled to mean 100, standard deviation 15; subtest scaled scores have mean 10, standard deviation 3. The Bayley-4 added digital administration for selected components. The contrast with the Denver II is a classic board distinction: Denver II screens, Bayley diagnoses. The shorter Bayley Infant Neurodevelopmental Screener (BINS) covers 3 to 24 months across 4 conceptual areas (neurological, receptive, expressive, cognitive) with risk categorized as low, moderate, or high, serving as a faster office screener.

The developmental quotient (DQ) equals (developmental age divided by chronological age) multiplied by 100. A DQ below 70 corresponds roughly to performance more than 2 standard deviations below the mean. In preterm infants the denominator must use corrected age until at least 24 months of age, and many experts continue correcting until 36 months for infants born before 28 weeks of gestation.

The 2022 CDC and AAP milestone revision was a significant methodologic shift. The updated checklists now reflect behaviors that at least 75 percent of children demonstrate at a given age, replacing the previous 50th-percentile standard. The revision eliminated vague qualifiers such as “may” and “begins” in favor of observable, binary criteria. The checklists span 12 age-specific forms covering every recommended well-child visit from 2 months through 5 years, with newly added 15-month and 30-month checklists. Approximately 60 percent of original milestones were retained with modifications and roughly 40 percent were newly added.